Search clinical trials for: REGN1908-1909

Total 560 results

Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Allergy

United States
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Regeneron Pharmaceuticals

Completed

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Cat Allergy | Mild Asthma

France
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Allergic Rhinitis Due to Cat Allergy

United States, Belgium, Germany, Poland, Canada, France
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

CD55-Deficient Protein-Losing Enteropathy
Regeneron Pharmaceuticals

Terminated

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Korea, Republic of, Malaysia, Hungary, Taiwan, United Kingdom
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Hypertriglyceridemia

United States
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Metabolic Disorders

United States
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab

Paroxysmal Nocturnal Hemoglobinuria (PNH) | CD55-deficient Protein-losing Enteropathy (PLE) | CD59 Deficiency
Regeneron Pharmaceuticals

Available

A Compassionate Use (CU) Program of Odronextamab

Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | B-Cell Non-Hodgkin Lymphoma (NHL) | High-Grade B-Cell Lymphoma (HGBCL)
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Advanced Malignant Cancer

China
Regeneron Pharmaceuticals

Completed

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Severe Hypertriglyceridemia (sHTG)

United States, Canada, Italy, United Kingdom
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Completed

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

Healthy Volunteer

Belgium
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Regeneron Pharmaceuticals

Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Australia, Austria, Netherlands, Taiwan, Ukraine
Yungjin Pharm. Co., Ltd.

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Korea, Republic of
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Nesvacumab (REGN910/ SAR307746)

Solid Tumors

United States, Canada
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Hong Kong, Hungary, United Kingdom
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hong Kong, Hungary, Korea, Republic of, Malaysia, United Kingdom
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Healthy

United Kingdom
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Hypertriglyceridemia

United States, Germany, Netherlands, Canada
Regeneron Pharmaceuticals

Completed

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, South Africa, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Ukraine
Regeneron Pharmaceuticals

Completed

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, United Kingdom
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (ROXI-CATH)

Venous Thromboembolism
Regeneron Pharmaceuticals

Recruiting

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2)

B-cell Non-Hodgkin Lymphoma (NHL)

United States, Korea, Republic of, China, Spain, Japan, United Kingdom, France, Taiwan, Singapore, Italy, Australia, Canada, Germany, Poland
Regeneron Pharmaceuticals

Active, not recruiting

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

CD55-deficient Protein-losing Enteropathy | CHAPLE

United States, Thailand, Turkey
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)

Generalized Myasthenia Gravis

Korea, Republic of, Japan, Spain, United States, Germany, Italy, Canada, Georgia, India, Belgium, Poland, Taiwan, Australia, Denmark, France, Turkey, Serbia, United Kingdom, Czechia
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Healthy

Belgium
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Long-term Safety, Tolerability, and Effectiveness of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS-EXT)

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Regeneron Pharmaceuticals

Active, not recruiting

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, United Kingdom, Israel, Germany, France
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

Hypercholesterolemia and Hyperlipidemia

China
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor

China
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Rakuten Medical, Inc.
National Cancer Institute (NCI); Shimadzu Corporation

Recruiting

ASP-1929 Photoimmunotherapy (PIT) Study in in Patients With Recurrent Head/Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Asthma

China
Atridia Pty Ltd.

Completed

A Trial of SHR-1905 in Healthy Subjects

Asthma

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

Hyperlipidemia

China
Regeneron Pharmaceuticals

Completed

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Canada
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors

China
University of Iowa
National Cancer Institute (NCI); Mayo Clinic; Pfizer

Completed

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Chronic Lymphocytic Leukemia

United States
Stanford University
National Institutes of Health (NIH)

Withdrawn

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Mycosis Fungoides

3

Subscribe